Nikhil Prasad Fact checked by:Thailand Medical News Team Jan 17, 2025 19 hours, 16 minutes ago
Medical News: In a groundbreaking study, researchers from Wenzhou Medical University, Ningbo University, and Nanjing University have uncovered a promising new avenue for treating Alzheimer’s disease. By targeting a specific protein in the brain’s blood vessels, the team has demonstrated significant improvements in cognitive function and reduced pathological hallmarks of the disease. This discovery may pave the way for innovative therapies to combat Alzheimer’s, which remains one of the most challenging neurodegenerative disorders to treat.
New Hope for Alzheimer’s Disease Treatment Targeting Cerebrovascular Protein
What is Alzheimer’s Disease?
Alzheimer’s disease, the leading cause of dementia worldwide, is characterized by progressive memory loss and cognitive decline. Its key pathological features include the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles in the brain. These changes disrupt communication between brain cells and lead to their eventual death. While most therapies focus on reducing amyloid-beta production or clearing these plaques, this
Medical News report explores a novel approach that targets a protein in cerebrovascular endothelial cells.
The Role of IFITM3 in Alzheimer’s Disease
The protein in question, interferon-induced transmembrane protein 3 (IFITM3), is primarily known for its role in the immune system. However, recent research has revealed its involvement in Alzheimer’s. In patients with Alzheimer’s and in mouse models of the disease, IFITM3 is overexpressed in the endothelial cells of the brain’s blood vessels. This overexpression leads to a harmful cycle: increased IFITM3 boosts the production of amyloid-beta, which in turn further raises IFITM3 levels.
The study demonstrated that high levels of IFITM3 activate enzymes such as beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase, which are directly involved in amyloid-beta production. The resulting amyloid-beta accumulation damages blood vessels, disrupts the blood-brain barrier (BBB), and impairs cognitive function.
Methodology and Findings
The research team employed advanced techniques, including single-nucleus RNA sequencing and mouse models, to investigate IFITM3’s role. By using a specialized viral vector to reduce IFITM3 expression in cerebrovascular endothelial cells, they observed remarkable improvements:
-Reduction in Amyloid-Beta Accumulation: Lower IFITM3 levels led to decreased amyloid-beta deposits in the brain’s blood vessels and surrounding tissues.
-Improved Blood-Brain Barrier Integrity: The knockdown of IFITM3 restored the expression of proteins essential for maintaining the BBB, such as claudin-5 and occludin.
-Enhanced Cognitive Performance: Mice with reduced IFITM3 levels showed significant improvements in memory and learning tasks
, including the Y-maze and Morris water maze tests.
Implications of the Findings
The study highlights the crucial role of cerebrovascular health in Alzheimer’s disease. Amyloid-beta accumulation in blood vessels is a hallmark of cerebral amyloid angiopathy, a condition closely linked to Alzheimer’s. The findings suggest that targeting IFITM3 can break the vicious cycle of amyloid-beta production and vascular damage.
This approach also has advantages over traditional therapies. Directly targeting amyloid-beta with immunotherapy has shown limited efficacy and significant side effects, particularly in advanced stages of the disease. By focusing on a protein that indirectly regulates amyloid-beta production, researchers aim to develop treatments with fewer adverse effects.
Future Directions
While the results are promising, further research is needed to translate these findings into clinical applications. Key areas for future investigation include:
-Drug Development: Identifying compounds that can safely and effectively inhibit IFITM3 in humans.
-Understanding Mechanisms: Exploring how IFITM3 interacts with other proteins and pathways involved in Alzheimer’s.
-Clinical Trials: Testing the safety and efficacy of IFITM3-targeting therapies in patients with early-stage Alzheimer’s.
Conclusion
This study represents a significant step forward in the fight against Alzheimer’s disease. By targeting the cerebrovascular protein IFITM3, researchers have uncovered a novel strategy to reduce amyloid-beta accumulation, improve vascular health, and enhance cognitive function. These findings offer hope for developing new treatments that address both the vascular and neurodegenerative aspects of Alzheimer’s. While much work remains, this research lays a strong foundation for future innovations.
The study findings were published in the peer-reviewed journal: Alzheimer’s & Dementia.
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14543
For the latest on Alzheimer, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/thailand-medical-and-pharmaceutical-study-explores-oroxylum-indicum-root-extract-to-treat-alzheimer-s-disease
https://www.thailandmedical.news/news/impact-of-covid-19-on-blood-brain-barrier-and-alzheimer-risk
https://www.thailandmedical.news/news/new-path-to-combat-alzheimer-s-unveiled-by-cholesterol-research
https://www.thailandmedical.news/news/thailand-medical-researchers-explore-the-use-of-kratom-to-treat-alzheimer-s-disease
https://www.thailandmedical.news/articles/alzheimer,-dementia-
Share
Tweet
Share
